Summary

This AI-generated content is provided without warranty, with no liability accepted for reliance on it. Learn more.

• This summary is based on the review of seven systematic review(s)/meta-analysis(es). ^[1-7]
• Sarilumab demonstrated significant efficacy in rheumatoid arthritis (RA) patients with inadequate response to tumor necrosis factor (TNF) inhibitors, achieving American College of Rheumatology (ACR) 20%, ACR50, and ACR70 responses. Sarilumab was comparable in overall efficacy to other biologics, including adalimumab and tocilizumab, but slightly less effective than tocilizumab in some comparisons.
• In polymyalgia rheumatica (PMR), Sarilumab was shown to be an approved corticosteroid-sparing therapy, effectively targeting the IL-6 signaling pathway. Additionally, Sarilumab was effective in managing non-infectious non-anterior uveitis (NINA uveitis).
• Sarilumab was superior to placebo in reducing fatigue in patients with inflammatory rheumatic and musculoskeletal diseases (I-RMDs), demonstrating efficacy in reducing fatigue over 24 weeks in RA patients.
• Sarilumab demonstrated a favorable safety profile across various inflammatory conditions, including RA and inflammatory rheumatic and musculoskeletal diseases (I-RMDs), with no significant safety concerns reported. It showed no notable differences in the incidence of adverse events or serious adverse events when compared to other biologic agents such as abatacept, rituximab, tocilizumab, and adalimumab.
• Sarilumab exhibited a comparable safety profile to other biologics in RA patients with inadequate response to TNF inhibitors, with no significant differences observed in adverse reactions, serious adverse reactions, or withdrawal due to adverse effects.
• Sarilumab was evaluated across various populations, including patients with RA who had an inadequate response to TNF inhibitors, showing significant improvement in ACR responses. It was also effective in reducing fatigue in adults with I-RMDs and demonstrated efficacy in managing NINA uveitis. Additionally, Sarilumab was highlighted as a corticosteroid-sparing option in PMR and giant cell arteritis (GCA), reflecting its potential across diverse inflammatory conditions.